Search Results

• • 18 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Potent cross-reactive antibodies following Omicron breakthrough in vaccinees.

  Authors:Rungtiwa Nutalai, Daming Zhou, Aekkachai Tuekprakhon, Helen M. Ginn, Piyada Supasa, Chang Liu, et al.From:Cell (Vol. 185, Issue 12) Peer-Reviewed

  June 9, 2022555 words Article

   Abstract Only

• SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.

  Authors:Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, Jirí Zahradník, Piyada Supasa, Chang Liu, et al.From:Cell (Vol. 185, Issue 3) Peer-Reviewed

  Feb. 3, 2022949 words Report

   Abstract Only

• The epitope arrangement on flavivirus particles contributes to Mab C10's extraordinary neutralization breadth across Zika and dengue viruses.

  Authors:Arvind Sharma, Xiaokang Zhang, Wanwisa Dejnirattisai, Xinghong Dai, Danyang Gong, Wiyada Wongwiwat, et al.From:Cell (Vol. 184, Issue 25) Peer-Reviewed

  Dec. 9, 2021547 words Report

   Abstract Only

• Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

  Authors:Rebecca P. Payne, Stephanie Longet, James A. Austin, Donal T. Skelly, Wanwisa Dejnirattisai, Sandra Adele, et al.From:Cell (Vol. 184, Issue 23) Peer-Reviewed

  Nov. 11, 2021958 words Report

   Abstract Only

• Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002).

  Authors:Amy Flaxman, Natalie G Marchevsky, Daniel Jenkin, Jeremy Aboagye, Parvinder K Aley, Brian Angus, et al.From:The Lancet (Vol. 398, Issue 10304) Peer-Reviewed

  Sept. 11, 20211,260 words Article

   Abstract Only

• Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

  Authors:Daming Zhou, Wanwisa Dejnirattisai, Piyada Supasa, Chang Liu, Alexander J. Mentzer, Helen M. Ginn, et al.From:Cell (Vol. 184, Issue 9) Peer-Reviewed

  Apr. 29, 2021650 words Report

   Abstract Only

• Cross-reacting antibodies enhance dengue virus infection in humans

  Authors:Wanwisa Dejnirattisai, Amonrat Jumnainsong, Naruthai Onsirisakul, Patricia Fitton, Sirijitt Vasanawathana, Wannee Limpitikul, et al.From:Science (Vol. 328, Issue 5979) Peer-Reviewed

  May 7, 2010131 words Author abstract, Rep...

   Abstract Only

• Therapeutic and protective efficacy of a dengue antibody against Zika infection in rhesus monkeys

  Authors:Peter Abbink, Rafael A. Larocca, Wanwisa Dejnirattisai, Rebecca Peterson, Joseph P. Nkolola, Erica N. Borducchi, et al.From:Nature Medicine (Vol. 24, Issue 6) Peer-Reviewed

  June 20183,291 words Report 1580LStrategies to treat Zika virus (ZIKV) infection in dengue virus (DENV)-endemic areas are urgently needed. Here we show that a DENV-specific antibody against the E-dimer epitope (EDE) potently cross-neutralizes ZIKV and...

• Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

  Authors:Juthathip Mongkolsapaya, Wanwisa Dejnirattisai, Xiao-ning Xu, Sirijitt Vasanawathana, Nattaya Tangthawornchaikul, Aroonrung Chairunsri, et al.From:Nature Medicine (Vol. 9, Issue 7) Peer-Reviewed

  July 20036,219 words Article Dengue virus presents a growing threat to public health in the developing world. Four major serotypes of dengue virus have been characterized, and epidemiological evidence shows that dengue hemorrhagic fever (DHF), the...

• The antigenic anatomy of SARS-CoV-2 receptor binding domain.

  Authors:Wanwisa Dejnirattisai, Daming Zhou, Helen M. Ginn, Helen M.E. Duyvesteyn, Piyada Supasa, James Brett Case, et al.From:Cell (Vol. 184, Issue 8) Peer-Reviewed

  Apr. 15, 2021813 words Report

   Abstract Only

• Structural basis of potent Zika-dengue virus antibody cross-neutralization

  Authors:Giovanna Barba-Spaeth, Wanwisa Dejnirattisai, Alexander Rouvinski, Marie-Christine Vaney, Iris Medits, Arvind Sharma, et al.From:Nature (Vol. 536, Issue 7614) Peer-Reviewed

  Aug. 4, 20166,319 words Article 1510LZika virus is a member of the Flavivirus genus that had not been associated with severe disease in humans until the recent outbreaks, when it was linked to microcephaly in newborns in Brazil and to Guillain-Barre...

• Erratum: Structural basis of potent Zikadengue virus antibody cross-neutralization

  Authors:Giovanna Barba-Spaeth, Wanwisa Dejnirattisai, Alexander Rouvinski, Marie-Christine Vaney, Iris Medits, Arvind Sharma, et al.From:Nature (Vol. 539, Issue 7628) Peer-Reviewed

  Nov. 10, 201685 words Brief article, Corre... 220LAuthor(s): Giovanna Barba-Spaeth; Wanwisa Dejnirattisai; Alexander Rouvinski; Marie-Christine Vaney; Iris Medits; Arvind Sharma; Etienne Simon-Lorire; Anavaj Sakuntabhai; Van-Mai Cao-Lormeau; Ahmed Haouz; Patrick...

• Lectin switching during dengue virus infection

  Authors:Wanwisa Dejnirattisai, Andrew I. Webb, Vera Chan, Amonrat Jumnainsong, Andrew Davidson, Juthathip Mongkolsapaya, et al.From:Journal of Infectious Diseases (Vol. 203, Issue 12) Peer-Reviewed

  June 15, 2011 Report

   Citation Only

• Immunodominant T-cell responses to dengue virus NS3 are associated with DHF

  Authors:Thaneeya Duangchinda, Wanwisa Dejnirattisai, Sirijit Vasanawathana, Wannee Limpitikul, Nattaya Tangthawornchaikul, Prida Malasit, et al.From:Proceedings of the National Academy of Sciences of the United States (Vol. 107, Issue 39) Peer-Reviewed

  Sept. 28, 2010166 words Author abstract, Rep...

   Abstract Only

• Antibody evasion by the P.1 strain of SARS-CoV-2.

  Authors:Wanwisa Dejnirattisai, Daming Zhou, Piyada Supasa, Chang Liu, Alexander J. Mentzer, Helen M. Ginn, et al.From:Cell (Vol. 184, Issue 11) Peer-Reviewed

  May 27, 2021744 words Report

   Abstract Only

• Recognition determinants of broadly neutralizing human antibodies against dengue viruses

  Authors:Alexander Rouvinski, Pablo Guardado-Calvo, Giovanna Barba-Spaeth, Stephane Duquerroy, Marie- Christine Vaney, Carlos M. Kikuti, et al.From:Nature (Vol. 520, Issue 7545) Peer-Reviewed

  Apr. 2, 20155,078 words Report 1500LDengue disease is caused by four different flavivirus (1) serotypes, which infect 390 million people yearly with 25% symptomatic cases (2) and for which no licensed vaccine is available. Recent phase III vaccine trials...

• Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

  Authors:Chang Liu, Helen M. Ginn, Wanwisa Dejnirattisai, Piyada Supasa, Beibei Wang, Aekkachai Tuekprakhon, et al.From:Cell (Vol. 184, Issue 16) Peer-Reviewed

  Aug. 5, 2021837 words Report

   Abstract Only

• Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

  Authors:Piyada Supasa, Daming Zhou, Wanwisa Dejnirattisai, Chang Liu, Alexander J. Mentzer, Helen M. Ginn, et al.From:Cell (Vol. 184, Issue 8) Peer-Reviewed

  Apr. 15, 2021664 words Report

   Abstract Only